Lonza, a contract development and manufacturing organization (CDMO), expanded its strategic collaboration with a leading US-based biopharmaceutical company, reinforcing a long-standing partnership focused on the commercial development and manufacturing of biologic medicines.
As part of the expanded agreement, Lonza will commercially manufacture two additional biologics programs, with options to add two more in the future. The latest expansion builds upon an established multi-year relationship that already includes long-term commitments across a diverse portfolio of biologics programs.
By broadening the collaboration, both companies aim to create a flexible manufacturing framework capable of adapting to changing market demand while reducing development risks. The partnership also enables seamless program scaling, from clinical development through to commercial production.
Multi-Billion CHF Partnership Reflects Strong Outsourcing Demand
Over the past several years, Lonza has consistently strengthened its relationship with the customer through a series of strategic agreements. Collectively, these contracts have the potential to reach a cumulative value of several billion Swiss francs (CHF).
The growing partnership highlights the increasing demand among global biopharmaceutical companies for outsourced manufacturing services. It also demonstrates the industry’s confidence in Lonza’s integrated development and commercial manufacturing capabilities.
Global Manufacturing Network Enhances Supply Security
Under the expanded collaboration, Lonza will deliver development and commercial manufacturing services through its network of large-scale biologics manufacturing facilities in the United States. These operations will be complemented by the company’s drug substance and drug product development and manufacturing capabilities across Europe.
This multi-site manufacturing strategy offers significant advantages, including enhanced geographic flexibility, improved supply chain resilience, and reliable access to specialized technologies. At the same time, it supports the customer’s long-term global growth strategy by ensuring secure and scalable production capacity.
Advanced Manufacturing Technologies Improve Efficiency
Lonza will utilize its extensive technology platform for mammalian antibody production, including advanced process intensification techniques such as N-1 perfusion, to optimize manufacturing efficiency. The company will implement manufacturing process improvements designed to significantly reduce production cycle times across selected biologics programs. These optimizations are expected to accelerate product delivery while maintaining high standards of quality and operational excellence.
End-to-End Biologics Development and Manufacturing Support
In addition to drug substance manufacturing, Lonza will provide comprehensive end-to-end services across the biologics value chain. These include drug product manufacturing and related support services, enabling a seamless transition from active pharmaceutical ingredients to the final dosage form. By integrating development, manufacturing, and fill-finish capabilities under one partnership, Lonza helps simplify complex supply chains while improving speed, quality, and reliability throughout the product lifecycle.
Lonza Reinforces Its Position as a Trusted CDMO Partner
Gordon Bates, Head of Integrated Biologics at Lonza, said, “This strategic collaboration demonstrates Lonza’s role as a trusted manufacturing partner for large biopharmaceutical companies. By combining cutting-edge science, smart technology and lean manufacturing in our global network, Lonza enables customers to advance complex portfolios, combining speed and flexibility with high quality and reliability.”
Strengthening the Future of Biologics Manufacturing
The expanded agreement further reinforces Lonza’s leadership in the global biologics CDMO market. As pharmaceutical companies increasingly seek reliable outsourcing partners with global manufacturing networks and advanced process technologies, Lonza continues to position itself as a preferred partner capable of supporting biologics from early development through commercial production. As per the press release, with scalable manufacturing capacity, integrated services, and continuous process innovation, the collaboration is expected to accelerate the delivery of next-generation biologic therapies while ensuring long-term supply security and operational excellence.
